Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma.

RS, Finn; YK, Kang; M, Mulcahy; BN, Polite; HY, Lim; I, Walters; C, Baudelet; D, Manekas; JW, Park

doi:10.1158/1078-0432.ccr-11-1991

Public

Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma.

Shared by NobleBlocks on Jan 11, 2012 • 12:00 AM UTC

Authors:

Finn RS

Kang YK

Mulcahy M

Abstract

<h4>Purpose</h4>Brivanib, a selective dual inhibitor of fibroblast growth factor and VEGF signaling, has recently been shown to have activity as first-line treatment for patients with advanced hepatocellular carcinoma (HCC). This phase II open-label study assessed brivanib as second-line therapy in ...

Discussions